secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001437749-25-026205
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

DiaMedica Therapeutics Reports Q2 2025 Financial Results and Positive Phase 2 Interim Data for DM199 in Preeclampsia
--------------------------------------------------------------------------------

- Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.
- Raised $30.1 million in July 2025 private placement, extending proforma cash to ~$60M and funding operations into H2 2027.
- ReMEDy2 Phase 2/3 trial for acute ischemic stroke enrollment progressing; interim analysis on first 200 patients expected Q2 2026.
- Appointed Julie Krop, MD, as Chief Medical Officer in August 2025; added to Russell 2000 and 3000 Indexes in June 2025.
- Net loss for Q2 2025 was $7.7 million, up from $5.1 million in Q2 2024; R&D expenses increased to $5.8 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/0001437749-25-026205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/dmtp20250811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer